Open AccessRemdesivir for 5 or 10 Days in Patients with Severe Covid-19
Author(s) -
Jason D. Goldman,
David Chien Lye,
David S.C. Hui,
Kristen Marks,
Raffaele Bruno,
Rocío Montejano,
Christoph D. Spinner,
Massimo Galli,
Mi-Young Ahn,
Ronald Nahass,
Yao-Shen Chen,
Devi SenGupta,
Robert H. Hyland,
Anu Osinusi,
Huyen Cao,
Christiana Blair,
Xuelian Wei,
Anuj Gaggar,
Diana M. Brainard,
William Towner,
José Muñóz,
Kathleen M. Mullane,
Francisco M. Marty,
Karen T. Tashima,
George Diaz,
Aruna Subramanian
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2015301
Subject(s) - covid-19 , virology , medicine , betacoronavirus , outbreak , disease , infectious disease (medical specialty)
Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom